Gyre Therapeutics, Inc. has grown revenue 4.5% a year over three years and 85% a year over five, with earnings per share compounding at −13%. Revenue growth, 3-year annual rate: +4.5% (Biotechnology median +17%). Revenue growth, 5-year rate: +85%, growth has slowed since the five-year average. Earnings per share, 3-year rate: −13%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 17, FY2009 to FY2025, as filed.

GYREGyre Therapeutics, Inc.

Healthcare

$6.76-7.0% 1Y

$6.76

$5.5652 weeks$8.87

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +14% year on year, but operating margin narrowing (−22.4 points).

1 good, 1 to watch, 1 without data

Revenue trend+14% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +85% a year.

Margin direction−22.4 points operating

Trailing-twelve-month operating margin, -17.0% now against 5.4% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is GYRE growing?

Gyre Therapeutics, Inc. has grown revenue 4.5% a year over three years and 85% a year over five, with earnings per share compounding at −13%.

+4.5%

Revenue growth, 3-year annual rate · Biotechnology median +17% · growing slowly · compounded from fiscal-year columns as filed

Revenue growth, 5-year rate: +85%
Revenue growth, 5-year rate · +4.5% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: −13%
Earnings per share, 3-year rate · revenue +4.5% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 17
Years of annual history on file · FY2009 to FY2025, as filed